LianBio
LianBio
LIANY
OTC
0.20
USD
0.00%
About
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications.
Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction.
TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 22.8K |
| Three Month Average Volume | 898.4K |
| High Low | |
| Fifty-Two Week High | 0.3888 USD |
| Fifty-Two Week Low | 0.05064 USD |
| Fifty-Two Week High Date | 15 Mar 2024 |
| Fifty-Two Week Low Date | 18 Oct 2023 |
| Price and Volume | |
| Current Price | 0.3275 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.13% |
| Thirteen Week Relative Price Change | -6.86% |
| Twenty-Six Week Relative Price Change | 60.30% |
| Fifty-Two Week Relative Price Change | 277.15% |
| Year-to-Date Relative Price Change | 62.49% |
| Price Change | |
| One Day Price Change | -6.43% |
| Thirteen Week Price Change | -0.32% |
| Twenty-Six Week Price Change | 76.25% |
| Five Day Price Change | -1.65% |
| Fifty-Two Week Price Change | 372.59% |
| Year-to-Date Price Change | 92.42% |
| Month-to-Date Price Change | 8.07% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.42772 USD |
| Book Value Per Share (Most Recent Quarter) | 1.88803 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.42772 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.88803 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.98055 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.02193 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.81947 USD |
| Normalized (Last Fiscal Year) | -1.02193 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.02193 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.81947 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.02193 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.81947 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.82466 USD |
| Cash Per Share (Most Recent Quarter) | 2.3535 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.01261 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.80758 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.782 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -11.00% |
| EPS Change (Trailing Twelve Months) | 22.30% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -252,222,000 |
| Net Debt (Last Fiscal Year) | -302,363,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 13 |
| Current Ratio (Most Recent Quarter) | 10 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -101,030,000 |
| Free Cash Flow (Trailing Twelve Months) | -83,991,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -29.56% |
| Return on Assets (Trailing Twelve Months) | -28.62% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -35.96% |
| Return on Equity (Trailing Twelve Months) | -37.03% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -34.46% |
| Return on Investment (Trailing Twelve Months) | -35.22% |
| Return on Investment (5 Year) | -99,999.99% |